Agilent Technologies, Inc.

Agilent Technologies to Collaborate with University of Toronto on Metabolomics MRM Library-Software Solution to Accelerate Cell Biology, Disease Research


Source: Agilent Technologies, Inc.

SANTA CLARA, Calif. -- Agilent Technologies, Inc. (NYSE: A) today announced a collaboration with scientists at the University of Toronto's Donnelly Centre for Cellular and Biomolecular Research to produce a comprehensive metabolomics multiple-reaction monitoring (MRM) library and methodology, using Agilent's Infinity 1290 UHPLC and 6460 triple quadrupole mass spectrometry system. The library, coupled with Agilent's MassHunter software, will provide scientists with a robust LC/MS solution to accelerate the quantification of hundreds of metabolically important compounds for cell biology and disease research.

'We are impressed with Agilent's mass spectrometry instruments and software solutions, and we look forward to working together to enable use of LC-MS metabolomics by a larger scientific audience,' said Professor Adam Rosebrock, who is collaborating on this project with Dr. Amy Caudy, both principal investigators from the Donnelly Centre.

'Routine metabolite quantification is an essential component for building a better understanding of how diseases such as cancer and diabetes modify metabolic pathways,' said Steve Fischer, market director for Agilent's Life Science Research Division. 'We are honored to work with Drs. Rosebrock and Caudy to bring this powerful solution to the scientific community and help advance research efforts in the area of quantitative metabolite measurement.'

When completed, this new metabolomics MRM library will be added to Agilent's existing collection of MRM libraries, which address a variety of applications including pesticides, veterinary drugs, forensics and toxicology.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at

On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the separation of Agilent's electronic measurement business; future revenues, earnings and profitability; the future demand for the company's products and services; and customer expectations. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers' businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.

In addition, other risks that Agilent faces include those detailed in Agilent's filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

Customer comments

No comments were found for Agilent Technologies to Collaborate with University of Toronto on Metabolomics MRM Library-Software Solution to Accelerate Cell Biology, Disease Research. Be the first to comment!